Interstitial lung disease (ILD) is a common sequela of systemic sclerosis (SSc) and is associated with significant morbidity and mortality. SSc-ILD is a heterogenous disorder without clear guidance on diagnosis, management, and follow-up. Pulmonary and extrapulmonary complications of SSc are common, with limited treatment options. Historically, mycophenolate and cyclophosphamide have served as the first-line treatments, while nintedanib and tocilizumab have recently emerged with new FDA approvals. Four cases are discussed in this activity by Flavia Castelino, MD, and Sonye Danoff, MD, PhD, that provide clinical insights into the risks of lung involvement, latest advances in guidelines and research, diagnostic testing, disease progression assessment, and shared decision-making. Join Drs. Castelino and Danoff for this active learning activity on the diagnosis and treatment of patients with SSc-ILD.
Course Credit:
1.50 AMA PRA Category 1 CreditsTM
Dates:
Opens: 2022-09-20
Closes: 2023-09-20
Target Audience:
This activity was developed for a national audience of pulmonologists, radiologists, rheumatologists, dermatologists, and primary care physicians, and other clinicians who have a role in the diagnosis and treatment of patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Accreditation and Certification
The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Additional Content Planners
Kam A. Newman, MD (Peer Reviewer)No significant relationships to disclose.
Michael Smith, PharmD (Medical Writer)
Consultant: Wolters-Kluwer
Annenberg Center for Health Sciences
Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.
All of the financial relationships listed for these individuals have been mitigated.
-
Flavia Castelino, MD
Director, Scleroderma Program
Division of Rheumatology
Massachusetts General Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts -
Sonye K. Danoff, MD, PhD
Associate Professor of Medicine
Johns Hopkins Medicine
Baltimore, Maryland
Presenting Faculty
Downloads
Learning Objectives
- Explain the risk for and symptoms suggestive of lung involvement in patients with scleroderma
- Discuss the latest advances in clinical guidelines and research related to systemic sclerosis-associated interstitial lung disease (SSc-ILD)
- Engage best practices in the diagnostic testing and disease-progression assessment of SSc-ILD
- Employ shared decision-making strategies to optimize health outcomes in patients with SSc-ILD, including in patients with associated comorbidities
Faculty Disclosures
Flavia Castelino, MD
Consultant: Boehringer Ingelheim
Sonye K. Danoff, MD, PhD
Advisory Board: Boehringer Ingelheim, CSL Behring
Consultant: Boehringer Ingelheim, Galapagos, Galecto,
Research Support: Boehringer Ingelheim, Bristol Myers Squibb
Royalties: UpToDate